Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition.

Cancer letters - 1 Jan 2022

Chen Fan, Liu Jinpeng, Song Xiulong, DuCote Tanner J, Byrd Aria L, Wang Chi, Brainson Christine F

Abstract excerpt

Members of the PI3K signaling pathway, especially PIK3CA, the gene encoding the catalytic subunit of the PI3K complex, are highly mutated and amplified in various cancer types, including non-small cell lung cancer. Although PI3K inhibitors have been used in clinics for follicular lymphoma and chronic lymphocytic leukemia, no agents targeting PI3K aberrations in lung cancer have been approved by the FDA so far. In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Biphenyl Compounds
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enhancer of Zeste Homolog 2 Protein

Share to Morpholines

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Pyridones

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 34655667
DOI: 10.1016/j.canlet.2021.10.010
PMCID: PMC8743034

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition.PMID 34655667Read ↗

The impact of heterogeneity in phosphoinositide 3-kinase pathway in human cancer and possible therapeutic treatments.Semantic proximity Read ↗

Suppression of RIPK3 by EZH2 contributes to cigarette smoking-induced chemoresistance in lung cancerSemantic proximity Read ↗

RHCG inhibition promotes the sensitivity of PIK3CA-mutant non-small lung cancer to PI3K inhibitor.Semantic proximity Read ↗

PIK3CA mutations and copy number gains in human lung cancers.Semantic proximity Read ↗

Exploiting an Epigenetic Resistance Mechanism to PI3 Kinase Inhibition in Leukemic Stem CellsSemantic proximity Read ↗

Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma.Semantic proximity Read ↗

Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.Semantic proximity Read ↗

Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.Semantic proximity Read ↗

PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancerSemantic proximity Read ↗

Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.Semantic proximity Read ↗

PIK3CAH1047R Accelerates and Enhances KRASG12D-Driven Lung TumorigenesisSemantic proximity Read ↗

PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.